Literature DB >> 3858014

Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia.

A D Pearson, A W Craft, E J Eastham, G W Aherne, P Littleton, G L Pearson, A N Campbell.   

Abstract

Serum methotrexate concentrations have been measured in 28 children with acute lymphoblastic leukaemia (ALL) following PO administration under standard conditions. Small-intestinal transit time, measured by the time taken for lactulose to pass from mouth to caecum, has been related with methotrexate absorption parameters. Small intestinal transit times ranged from 30 to 240 min. Children with longer transit times had later times of peak methotrexate concentration and tended to have a more erratic methotrexate absorption profile with two peaks. There appears to be an optimal transit time between 90 and 105 min for methotrexate absorption, with both faster and slower small-intestinal transit times producing lower peak concentrations as a fraction of the dose.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3858014     DOI: 10.1007/bf00258118

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  31 in total

1.  Use of breath hydrogen (H2) to quantitate small bowel transit time following partial gastrectomy.

Authors:  J H Bond; M D Levitt
Journal:  J Lab Clin Med       Date:  1977-07

2.  A pH-dependent, carrier-mediated transport system for the folate analog, amethopterin, in rat jejunum.

Authors:  W B Strum
Journal:  J Pharmacol Exp Ther       Date:  1977-12       Impact factor: 4.030

3.  Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells.

Authors:  P L Chello; F M Sirotnak; D M Dorick; R C Donsbach
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

4.  Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements.

Authors:  J H Bond; M D Levitt; R Prentiss
Journal:  J Lab Clin Med       Date:  1975-04

5.  Pharmacokinetics of oral methotrexate in children.

Authors:  F M Balis; J L Savitch; W A Bleyer
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

6.  Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia.

Authors:  P J Kearney; P A Light; A Preece; M G Mott
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  A new method for the detection of hydrogen in breath and its application to acquired and inborn sugar malabsorption.

Authors:  K Bartlett; J V Dobson; E Eastham
Journal:  Clin Chim Acta       Date:  1980-12-08       Impact factor: 3.786

8.  Plasma methotrexate as determined by liquid chromatography, enzyme-inhibition assay, and radioimmunoassay after high-dose infusion.

Authors:  S K Howell; Y M Wang; R Hosoya; W W Sutow
Journal:  Clin Chem       Date:  1980-05       Impact factor: 8.327

9.  Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient.

Authors:  M A Evans; G A Broe; E J Triggs; M Cheung; H Creasey; P D Paull
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

10.  Development and application of a radioimmunoassay for methotrexate.

Authors:  G W Aherne; E M Piall; V Marks
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

View more
  4 in total

Review 1.  Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.

Authors:  J M Greiff; D Rowbotham
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

2.  Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.

Authors:  A D Pearson; S Mills; H A Amineddine; D R Long; A W Craft; J M Chessells
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate.

Authors:  P Sonneveld; F W Schultz; K Nooter; K Hählen
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  The effect of food on the oral administration of 6-mercaptopurine.

Authors:  N K Burton; M J Barnett; G W Aherne; J Evans; I Douglas; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.